WallStSmart
FLNA

Filana Therapeutics, Inc.

NASDAQ: FLNA · HEALTHCARE · BIOTECHNOLOGY

$1.20
-5.71% today

Updated 2026-06-05

Market cap
$63.77M
P/E ratio
P/S ratio
2.54x
EPS (TTM)
$-1.61
Dividend yield
52W range
$1 – $5
Volume
0.4M

Filana Therapeutics, Inc. (FLNA) Financial statements

SEC filings — annual and quarterly data.

Balance sheet — annual

Item20212022202320242025
Total assets$234.83M$151.66M$157.53M$118.36M
Cash & equivalents$201.01M$121.14M$128.57M$95.50M
Current assets$211.23M$129.63M$136.53M$97.71M
Total liabilities$7.29M$14.20M$11.83M$43.95M
Current liabilities$7.06M$14.20M$11.75M$43.83M
Long-term debt
Shareholder equity$227.54M$137.47M$145.70M$74.40M
Retained earnings$-283.55M$-380.77M$-405.11M$-496.08M
Accounts receivable$120000.00
Inventory
Goodwill

Frequently asked questions

How much free cash flow does FLNA generate?

FLNA produced $-32.83M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is FLNA's balance sheet healthy?

FLNA holds $95.50M in cash and equivalents against — in long-term debt, on $74.40M of shareholder equity. That debt is best read against the cash flow the business throws off each year.